Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Current Leases (2021 - 2026)

Aura Biosciences filings provide 6 years of Current Leases readings, the most recent being $3.3 million for Q1 2026.

  • Quarterly Current Leases rose 2.99% to $3.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Mar 2026, up 2.99% year-over-year, with the annual reading at $3.2 million for FY2025, 2.99% up from the prior year.
  • Current Leases hit $3.3 million in Q1 2026 for Aura Biosciences, up from $3.2 million in the prior quarter.
  • Across five years, Current Leases topped out at $3.3 million in Q1 2026 and bottomed at $624000.0 in Q1 2022.
  • Average Current Leases over 5 years is $2.7 million, with a median of $3.0 million recorded in 2023.
  • The largest annual shift saw Current Leases surged 384.68% in 2022 before it dropped 9.31% in 2023.
  • Aura Biosciences' Current Leases stood at $3.0 million in 2022, then fell by 9.31% to $2.7 million in 2023, then rose by 17.19% to $3.1 million in 2024, then rose by 2.99% to $3.2 million in 2025, then grew by 0.74% to $3.3 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Current Leases are $3.3 million (Q1 2026), $3.2 million (Q4 2025), and $3.2 million (Q3 2025).